Sensei Biotherapeutics Reports Shareholder Vote Matters

Ticker: SNSE · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1829802

Sensei Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySensei Biotherapeutics, Inc. (SNSE)
Form Type8-K
Filed DateJun 13, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: shareholder-vote, corporate-governance

TL;DR

Sensei Biotherapeutics held a shareholder vote on June 11th, impacting common and preferred stock.

AI Summary

Sensei Biotherapeutics, Inc. filed an 8-K on June 13, 2024, reporting on matters submitted to a vote of security holders on June 11, 2024. The filing details actions related to common stock and Series A preferred stock.

Why It Matters

This filing indicates that Sensei Biotherapeutics held a shareholder vote, which could lead to changes in corporate governance or strategic direction.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not indicate immediate financial distress or significant operational changes.

Key Players & Entities

  • Sensei Biotherapeutics, Inc. (company) — Registrant
  • June 11, 2024 (date) — Date of earliest event reported
  • June 13, 2024 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation
  • Rockville, MD (location) — Principal Executive Offices

FAQ

What specific matters were submitted to a vote of Sensei Biotherapeutics' security holders on June 11, 2024?

The filing indicates that matters were submitted to a vote of security holders on June 11, 2024, relating to common stock and Series A preferred stock, but the specific proposals are not detailed in this excerpt.

What is the principal business of Sensei Biotherapeutics, Inc.?

Sensei Biotherapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.

Where are Sensei Biotherapeutics, Inc.'s principal executive offices located?

The principal executive offices are located at 1405 Research Blvd, Suite 125, Rockville, MD 20850.

What is the fiscal year end for Sensei Biotherapeutics, Inc.?

The fiscal year end for Sensei Biotherapeutics, Inc. is December 31st.

What is the Commission File Number for Sensei Biotherapeutics, Inc.?

The Commission File Number for Sensei Biotherapeutics, Inc. is 001-39980.

Filing Stats: 567 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-06-13 16:45:34

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sensei Biotherapeutics, Inc. Date: June 13, 2024 /s/ Christopher W. Gerry Christopher W. Gerry General Counsel and Secretary 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.